LAG3 and cancer: Peptide LAG-3 inhibitors—both selective inhibitors of the LAG-3/FGL1 pathway, such as LFP-6 and LFP-D1, and cyclic LAG-3/MHC-II inhibitors, such as peptide 12—represent two complementary approaches to modulate LAG-3 function in cancer immunotherapy.